Iris Melanoma
15
0
1
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.3%
2 terminated out of 15 trials
85.7%
-0.8% vs benchmark
7%
1 trials in Phase 3/4
75%
9 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (15)
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma